Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/16591
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMangogna, A-
dc.contributor.authorBelmonte, B-
dc.contributor.authorAgostinis, C-
dc.contributor.authorGiuseppe, R-
dc.contributor.authorGulino, A-
dc.contributor.authorFerrara, I-
dc.contributor.authorZanconati, F-
dc.contributor.authorTripodo, C-
dc.contributor.authorRomano, F-
dc.contributor.authorKishore, U-
dc.contributor.authorBulla, R-
dc.date.accessioned2018-07-19T13:16:39Z-
dc.date.available2018-07-16-
dc.date.available2018-07-19T13:16:39Z-
dc.date.issued2018-
dc.identifier.citationFrontiers in Immunology, 2018en_US
dc.identifier.issn1664-3224-
dc.identifier.issnhttp://dx.doi.org/10.3389/fimmu.2018.01748-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/16591-
dc.description.abstractSurfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin (collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary existence. In the lungs, it is a well-established opsonin that can agglutinate a range of microbes, and enhance their clearance via phagocytosis and super-oxidative burst. It can interfere with allergen-IgE interaction and suppress basophil and mast cell activation. However, it is now becoming evident that SP-D is likely to be an innate immune surveillance molecule against tumor development. SP-D has been shown to induce apoptosis in sensitized eosinophils derived from allergic patients and a leukemic cell line via p53 pathway. Recently, SP-D has been shown to suppress lung cancer progression via interference with the epidermal growth factor signaling. In addition, a truncated form of recombinant human SP-D has been reported to induce apoptosis in pancreatic adenocarcinoma via Fas-mediated pathway in a p53-independent manner. To further establish a correlation between SP-D presence/levels and normal and cancer tissues, we performed a bioinformatics analysis, using Oncomine dataset and the survival analysis platforms Kaplan-Meier plotter, to assess if SP-D can serve as a potential prognostic marker for human lung cancer, in addition to human gastric, breast and ovarian cancers. We also analyzed immunohistochemically the presence of SP-D in normal and tumor human tissues. We conclude that (1) in the lung, gastric and breast cancers, there is a lower expression of SP-D than normal tissues; (2) in ovarian cancer, there is a higher expression of SP-D than normal tissue; and (3) in lung cancer, the presence of SP-D could be associated with a favorable prognosis. On the contrary, at non-pulmonary sites such as gastric, breast and ovarian cancers, the presence of SP-D could be associated with unfavorable prognosis. Correlation between the levels of SP-D and overall survival requires further investigation. Our analysis involves a large number of dataset; therefore, any trend observed is reliable. Despite apparent complexity within the results, it is evident that cancer tissues that produce less levels of SP-D compared to their normal tissue counterparts, are probably less susceptible to SP-D-mediated immune surveillance mechanisms via infiltrating immune cells.en_US
dc.language.isoenen_US
dc.publisherFrontiers Mediaen_US
dc.titlePathological significance and prognostic value of Surfactant Protein D in canceren_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.3389/fimmu.2018.01748-
dc.relation.isPartOfFrontiers in Immunology-
pubs.publication-statusAccepted-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf4.01 MBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.